Radiopharmaceutical · Acts on microRNA-10b (miR-10b) · developed by TransCode Therapeutics
Copper Cu 64 NODAGA-TTX-MC138 is a radiopharmaceutical comprising an anti-miR-10b antagomir conjugated to ultrasmall iron oxide nanoparticles and radiolabeled with copper Cu 64. It targets microRNA-10b in tumor cells for PET-MRI imaging of miR-10b-overexpressing metastatic tumors. The drug is studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05908773 | Early Phase 1 | Advanced Solid Tumor | Completed | RNAZ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumor
Updated Oct 3, 2026. Something wrong or missing? Report it on the RNAZ page.
See RNAZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RNAZ catalysts and pipeline →